Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of LY-CovMab Injection in Chinese Healthy Subjects

NCT04973735 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT04973735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of LY-CovMab Injection in Chinese Healthy Subjects
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 10, 2020
Completion date
July 31, 2021
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19